Interpace Biosciences Inc Forward P/E
What is the Forward P/E of Interpace Biosciences Inc?
The Forward P/E of Interpace Biosciences Inc is -0.76
What is the definition of Forward P/E?
Forward price to earnings ratio is the ratio of a company’s stock price to the company’s estimated earnings per share for the next twelve months.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Forward P/E of companies in the Health Care sector on NASDAQ compared to Interpace Biosciences Inc
What does Interpace Biosciences Inc do?
advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.
Companies with forward p/e similar to Interpace Biosciences Inc
- Neuronetics Inc has Forward P/E of -0.79
- Cara Therapeutics Inc has Forward P/E of -0.78
- Magenta Therapeutics Inc has Forward P/E of -0.78
- Dynatronics has Forward P/E of -0.78
- Onconova Therapeutics Inc has Forward P/E of -0.78
- Energous Corp has Forward P/E of -0.77
- Interpace Biosciences Inc has Forward P/E of -0.76
- Milestone Pharmaceuticals Inc has Forward P/E of -0.76
- Sonnet BioTherapeutics Inc has Forward P/E of -0.75
- Aspen Inc has Forward P/E of -0.75
- Aclaris Therapeutics Inc has Forward P/E of -0.74
- MusclePharm has Forward P/E of -0.74
- Karyopharm Therapeutics Inc has Forward P/E of -0.73